Objective: To determine if the study drug selpercatinib, compared to a standard treatment, is effective and safe in participants with RET fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Inclusion Criteria: Participants: … Read More
NSCLC
![](https://www.visualmed.org/wp-content/uploads/2023/06/KEYNOTE-671.jpg)
KEYNOTE 671 Trial: Perioperative Pembrolizumab in Early-Stage NSCLC
KEYNOTE 671 Trial Summary Introduction:The KEYNOTE 671 trial aimed to investigate the efficacy of perioperative pembrolizumab, an immune checkpoint inhibitor, in patients with resectable early-stage non–small-cell lung cancer (NSCLC). This randomized, double-blind, phase 3 trial assessed the benefits of neoadjuvant … Read More
![](https://www.visualmed.org/wp-content/uploads/2022/11/ALEX.jpg)
ALEX Trial Summary: Alectinib vs. Crizotinib in NSCLC
2017 ALEX TRIAL Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer international, open-label, randomised phase 3 trial Σ Objective: To compare alectinib (600 mg twice daily) with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with … Read More